entertainment -WSS

entertainment

author：entertainment 2025-08-11 07:58:42 - browse：96988

DENVER — He could have been a rock star, a religious icon, the way ecstatic applause from thousands of attendees greeted the man dressed in a crisp, all-white suit as he strode onto a backlit stage. He was neither. This was Rick Doblin, the founder and evangelist of a movement to legalize psychedelic MDMA and bring the drug into mainstream medicine.

The scene in a Denver conference hall last week was a world away from the first conference Multidisciplinary Association for Psychedelic Studies (MAPS) held in 1990, when Doblin spoke alongside Timothy Leary — the ex-Harvard professor who popularized the phrase “turn on, tune in, and drop out.” That was just a few years after MDMA, also known as ecstasy, was criminalized, deemed a Schedule 1 drug “of no medical use.”

Now, as MAPS nears its goal of winning Food and Drug Administration approval for MDMA as a treatment for post-traumatic stress disorder, the perpetually smiling and energetic Doblin is basking in the adoration from both legions of “psychonauts” and unlikely yet powerful allies. “I literally love Rick Doblin,” the conservative Republican and former Texas governor Rick Perry told the audience in Denver.

It was a seemingly triumphant occasion. But even as Doblin is in sniffing distance of his lifelong quest, his once counter-cultural organization is grappling with the pressures of having to operate in the capitalist pharmaceutical sphere. MAPS was founded in 1986 as a nonprofit with deep-seated ideals. Doblin developed an “anti-patent” strategy, putting discoveries in the public domain so they couldn’t be claimed as intellectual property. He raised money to fund clinical trials of MDMA from like-minded wealthy donors.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medical records are filled with copy
Next article： Chris Christie meets with Zelenskyy during Ukraine trip

explore

entertainment

WSS

2 officers injured in shooting in Orlando, police say

Readout Newsletter: Medeor's stem cell study, Moderna's stock dip

How neuroscience research could help beat back brain cancer

Key Senate panel to consider PBM, drug pricing reform package

What is microchimerism and how does it affect maternal health?

Florida officials tell state schools to teach AP Psychology 'in its entirety'

focus

entertainment

focus

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Flint parents haunted by uncertainty, fears of lead poisoning

Medical records are filled with copy

Biotech startup Celsius cuts 75% of staff ahead of first trial start

Hollywood unions extend contract negotiations for actors

Explaining an after

The high cost of giving birth even with insurance

How to convince healthy people to buy insurance

Apple is now the first public company to be valued at $3 trillion

How to convince healthy people to buy insurance

hotspot

Medicare slashes safety net hospital payments by nearly $1 billion

A controversial new treatment promises to make little people taller

Infant mortality in U.S. rose last year for first time in decades: CDC

Coloradans with cystic fibrosis could lose access to Trikafta

Personalized medicine goes far beyond genetics

Sarepta Duchenne therapy fails to meet primary endpoint in trial

explore

entertainment

focus

entertainment